清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab

医学 美罗华 淋巴瘤 CD47型 CD20 内科学 免疫组织化学 免疫学 抗体 肿瘤科 癌症研究
作者
Roy L. Maute,James Y. Chen,Kristopher D. Marjon,Jiaqi Duan,Timothy Choi,Mark P. Chao,Chris H. Takimoto,Balaji Agoram,Jens-Peter Volkmer
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 5229-5229 被引量:2
标识
DOI:10.1182/blood-2019-127526
摘要

Introduction Magrolimab (Hu5F9-G4, 5F9) is a first-in-class IgG4 antibody targeting CD47, a macrophage immune checkpoint and "don't eat me" signal expressed on cancer cells. Blockade of CD47 leads to phagocytosis of tumor cells. Magrolimab synergizes with rituximab to eliminate CD20-positive lymphoma by enhancing antibody-dependent cellular phagocytosis. Magrolimab +rituximab demonstrated encouraging safety and efficacy in a Phase (Ph)1b dose escalation cohort in patients with relapsed/refractory (r/r) DLBCL and FL that were rituximab-refractory (Advani et al., NEJM 2018). CD24 is an additional "don't eat me" signal, and has been proposed as a potential target for immunotherapy (Barkal et al. Nature 2019). Here we describe immunohistochemical analysis of CD47 and CD24 in primary patient biopsies from an ongoing follow-up Phase 2 trial of Non-Hodgkin's lymphoma (including DLBCL and indolent lymphoma) patients treated with magrolimab+rituximab. Results By immunohistochemistry, 54 out of 54 patients assessed were positive for expression of CD47 at screening. High levels of CD47 expression were maintained during treatment with clinically-efficacious doses of magrolimab. Therapeutic response did not correlate with CD47 H-score expression levels. At screening, patients presented with highly variable levels of CD24 expression, with 40 of 54 samples showing positive staining in >30% of cells. We observed no significant correlation between CD24 expression by H-score and response to therapy (complete response + partial response) in either DLBCL or indolent lymphoma. Conclusions CD47 shows consistently high expression in primary biopsies from Non-Hodgkin's lymphoma patients and remains persistently high during treatment. In our Phase 2 trial, therapeutic response did not correlate with CD47 expression levels, suggesting that the degree of target expression is not a primary driver of magrolimab efficacy in Non-Hodgkin's lymphoma. Although we observe wide variation in CD24 expression within this cohort, its levels are not predictive of outcome for this disease indication. We are evaluating the expression of additional biomarkers to identify those Non-Hodgkin's lymphoma patients most likely to benefit from magrolimab+rituximab combination therapy. Disclosures Maute: Forty Seven Inc.: Employment, Equity Ownership, Patents & Royalties. Chen:Forty Seven Inc.: Consultancy, Equity Ownership. Marjon:Forty Seven Inc.: Employment, Equity Ownership. Duan:Forty Seven Inc.: Employment, Equity Ownership. Choi:Forty Seven Inc.: Employment, Equity Ownership. Chao:Forty Seven, Inc.: Employment, Equity Ownership, Patents & Royalties. Takimoto:Forty Seven, Inc.: Employment, Equity Ownership, Patents & Royalties. Agoram:Forty Seven Inc.: Employment, Equity Ownership. Volkmer:Forty Seven, Inc.: Employment, Equity Ownership, Patents & Royalties.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
15秒前
22秒前
27秒前
标致的大船完成签到,获得积分10
30秒前
null的应助被科研通管家采纳,获得10
37秒前
null的应助被科研通管家采纳,获得10
37秒前
null的应助被科研通管家采纳,获得10
37秒前
n01W97的应助被科研通管家采纳,获得20
37秒前
罗密欧与傅里叶完成签到,获得积分10
39秒前
谦让的鹤轩完成签到,获得积分10
47秒前
戴肉肉完成签到 ,获得积分10
1分钟前
善良的梦曼完成签到,获得积分10
1分钟前
CodeCraft的应助被dianeil采纳,获得10
1分钟前
1分钟前
跳跃的冰安完成签到,获得积分10
1分钟前
dianeil发布了新的文献求助10
1分钟前
热心剑成完成签到,获得积分10
2分钟前
曾经的冰安完成签到,获得积分10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
rarity完成签到 ,获得积分10
2分钟前
积极的向彤完成签到,获得积分10
2分钟前
完美觅山完成签到,获得积分10
3分钟前
梅梅美美完成签到 ,获得积分10
3分钟前
清爽的口红完成签到,获得积分10
3分钟前
认真的狗发布了新的文献求助20
3分钟前
虚幻唯雪完成签到,获得积分10
4分钟前
我是老大的应助被LeoAllen849采纳,获得40
4分钟前
nk完成签到 ,获得积分10
4分钟前
4分钟前
剁辣椒蒸鱼头完成签到 ,获得积分10
4分钟前
冷酷紫烟完成签到,获得积分10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
科研通AI65的应助被海宁采纳,获得10
4分钟前
4分钟前
怕孤独的梦寒完成签到,获得积分10
4分钟前
风中黎昕完成签到 ,获得积分10
4分钟前
海宁发布了新的文献求助10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185392
求助须知:如何正确求助?哪些是违规求助? 9574120
关于积分的说明 21834329
捐赠科研通 7782811
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481272